Ipamorelin

Summary

Ipamorelin is a synthetic five-amino-acid peptide (a "pentapeptide") that tells the pituitary gland to release a pulse of growth hormone (GH). It belongs to a class called growth hormone secretagogues and works by mimicking ghrelin at the ghrelin/GH-secretagogue receptor. Its claim to fame, from the 1998 paper that introduced it, is selectivity: it triggers GH release without meaningfully raising stress hormones like cortisol and ACTH the way older peptides (GHRP-6, GHRP-2) do. It is sold online and in wellness clinics for muscle growth, fat loss, recovery, sleep, and anti-aging — usually paired with CJC-1295. The honest state of the evidence is upside-down from that marketing: ipamorelin reliably produces a short GH pulse (shown in animals and a small human pharmacology study), but the only times it was put to a real human efficacy test — Phase 2 trials for a gut condition — it failed, and there are no human trials at all for the muscle, fat-loss, or anti-aging uses it's actually sold for. It is an abandoned drug candidate, not FDA-approved, and cannot be legally compounded.

What people use it for

In bodybuilding, biohacker, and "anti-aging" communities, ipamorelin is injected (usually subcutaneously, often at night) to raise growth hormone with the goal of building muscle, losing fat, speeding recovery, improving deep sleep, strengthening skin/connective tissue, and slowing aging. It is most often used in combination with CJC-1295, a GHRH analog that works on a different receptor, on the theory that hitting both the GHRH and ghrelin pathways produces a larger, longer GH release. These are the claims the evidence sections test; describing them is not endorsement.

Human evidence

There is no human evidence that ipamorelin does any of the things it is marketed for. This is the single most important fact about it, and it has two parts.

First, the only controlled human trials of ipamorelin were for postoperative ileus — the slowing of the gut that can follow abdominal surgery — a logical target because ghrelin-receptor agonists promote gastrointestinal motility. Helsinn Therapeutics ran Phase 2, placebo-controlled trials for this indication. They did not show a meaningful benefit over placebo, and development was discontinued before Phase 3. So the one use ipamorelin was rigorously tested for in people, it failed — and that use is not even what it's sold for.

Second, the human data that does look supportive is narrow and is about a biomarker, not a benefit. A 1999 Phase 1 clinical-pharmacology study (Gobburu et al., Pharmaceutical Research) gave single intravenous doses of ipamorelin to healthy men and showed it produced a clean, dose-proportional pulse of growth hormone with a short half-life (about 2 hours). That confirms ipamorelin raises GH acutely in humans — but raising a hormone level for an hour is not the same as building muscle, losing fat, or living longer, and no human study has tested whether the GH pulse translates into any of those outcomes. There are no human trials of ipamorelin for muscle growth, body composition, athletic recovery, sleep, or aging.

Animal / preclinical evidence

The preclinical case is where ipamorelin's reputation comes from, and it is genuinely where the molecule was best characterized. In the foundational 1998 study (Raun et al.), ipamorelin released GH potently in cell and animal systems (rats and swine) and — importantly — did so selectively, without raising ACTH or cortisol above the levels seen with GHRH, distinguishing it from earlier GH-releasing peptides. Animal work also showed it increased food intake and body-weight gain, consistent with its ghrelin-like activity, which is part of why it was later tested for gut motility. A 2020 review of the growth-hormone-secretagogue class summarizes this lineage and notes that ipamorelin was the first GHRP-receptor agonist with GH-release selectivity comparable to GHRH.

The caveats are the usual translational ones, and they bite harder here because the human follow-through is so thin: animal GH-release and weight-gain findings do not establish that the peptide produces meaningful muscle, fat-loss, recovery, or longevity benefits in people, and the one human efficacy program that was attempted (for ileus) did not pan out.

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

Users commonly report better sleep, faster recovery, mild fat loss, improved skin, and a general sense of well-being over a cycle of ipamorelin (typically combined with CJC-1295), based on personal experience rather than controlled comparison. Because ipamorelin reliably nudges GH upward, and because GH is culturally associated with youth and performance, the subjective reports are unsurprising — but they are exactly what expectation, a real hormonal effect with no measured outcome, and the placebo response would produce, which is why controlled trials matter and why their absence here is the whole point. The CJC-1295 + ipamorelin "stack" is a community protocol, not an evidence-based regimen; there is no controlled human study of the combination for any of its marketed uses.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

The only published human dosing of ipamorelin comes from the 1999 Phase 1 pharmacology study, which used single intravenous infusions across a range of doses in healthy volunteers to characterize GH release — a clinical-pharmacology setting, not a therapeutic protocol. The subcutaneous "cycling" doses circulating in the community (and the bedtime CJC-1295 + ipamorelin protocols discussed on podcasts) are not derived from published human efficacy trials and are not reproduced here as guidance. Because there is no approved, quality-controlled product and no validated human regimen, there is no established dose.

Safety & side effects

The human safety profile of ipamorelin is not established, because it was never developed to approval and has no long-term human safety data for the way people actually use it (repeated subcutaneous injection over weeks to months). The short human exposures that exist — single doses in the Phase 1 study and the postoperative-ileus trials — did not flag dramatic acute harms, but they were small, brief, and not designed to detect the risks of chronic use. The FDA, in placing ipamorelin on its compounding "Category 2" list, cited insufficient safety information and concerns that included potential heart-related adverse events.

The more meaningful concerns are mechanistic. Anything that chronically raises growth hormone and, downstream, IGF-1 carries the known risks of GH excess — insulin resistance and higher blood sugar, fluid retention, joint pain, and carpal-tunnel-type symptoms — and a long-standing theoretical concern that sustained GH/IGF-1 elevation could promote the growth of existing tumors (GH and IGF-1 are growth signals). No direct ipamorelin–cancer link has been demonstrated, but this is an unstudied area, not a cleared one. Because ipamorelin also activates the ghrelin (hunger) pathway, increased appetite is a plausible effect — somewhat at odds with the fat-loss goal. Finally, the practical risk: gray-market "research only" vials are unregulated and may be underdosed, contaminated, or not contain what the label claims.

Regulatory / legal status

Ipamorelin is not FDA-approved for any use. It is, in effect, an abandoned drug candidate — developed by Novo Nordisk in the 1990s, tested for postoperative ileus, and dropped when it didn't work — now sold as a "research only" chemical rather than through any legitimate medical channel.

Its compounding status has moved around and is easy to misread. In 2023 the FDA placed ipamorelin (and CJC-1295) on the interim 503A "Category 2" list — bulk substances that may present significant safety risks, effectively off-limits for compounding. In September 2024 it was removed from Category 2 — but only because the nominations to add it to the approved 503A bulks list were withdrawn, a procedural change that does not authorize compounding. At the Pharmacy Compounding Advisory Committee meetings in late 2024, the FDA's own analysis recommended against adding ipamorelin to the 503A bulks list. The practical upshot as of this writing: ipamorelin is neither approved nor on the approved compounding list, so it cannot be lawfully compounded, and it reaches consumers only through unregulated research-chemical channels. Broader peptide-compounding policy is in active flux in 2026 amid political pressure to widen access (the same dynamic described in the BPC-157 brief), so this status could change — but "the rules might loosen" is not the same as "proven safe and effective."

In sport, the World Anti-Doping Agency prohibits ipamorelin at all times (in and out of competition) under category S2 (peptide hormones / growth-hormone secretagogues), and a therapeutic-use exemption would not be granted. Status varies by country and can change; this is not legal advice.

Podcast / media mentions

Ipamorelin is a staple of longevity and peptide-focused podcasts and clinic marketing, where it is usually presented — often alongside CJC-1295 — as a "clean," selective way to raise growth hormone for better sleep, recovery, body composition, and aging. The selectivity part is real and traces to legitimate pharmacology. The leap worth scrutinizing is from "it raises growth hormone" to "therefore it will recomposition your body and slow aging," because that second step has no human evidence behind it and the one human efficacy program (for ileus) failed. As always, the critique is of the certainty attached to the claims — a short GH pulse is not a demonstrated health benefit — not of the people discussing the molecule.